论文部分内容阅读
Sorafenib is the first-line drug for advanced hepatocellular carcinoma(HCC),but the clinical response to sorafenib is seriously limited by drug resistance.In this study,we investigated the molecular mechanisms of sorafenib resistance in HCC cells.Our data indicate that FoxM1 was significantly over-expressed in sorafenib-resistant cells,both at mRNA and protein levels.